1356011-59-0

Basic information

• Product Name: methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridin-3-yl]pyrimidin-5-yl} (2,2,2-trifluoroethyl)carbamate
• Synonyms: methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridin-3-yl]pyrimidin-5-yl} (2,2,2-trifluoroethyl)carbamate
• CAS NO: 1356011-59-0
• Molecular Weight: 490.42
• Mol File: 1356011-59-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridin-3-yl]pyrimidin-5-yl} (2,2,2-trifluoroethyl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridin-3-yl]pyrimidin-5-yl} (2,2,2-trifluoroethyl)carbamate(1356011-59-0)
• EPA Substance Registry System: methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridin-3-yl]pyrimidin-5-yl} (2,2,2-trifluoroethyl)carbamate(1356011-59-0)

Safety Data

• Hazardous Substances Data: 1356011-59-0(Hazardous Substances Data)

Upstream product

• 23199-56-6 2,2,2-trifluoroethyltrichloromethanesulfonate 

Downstream Products

• 1361569-22-3 2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-7-(2,2,2-trifluoroethyl)-7,9-dihydro-8H-purin-8-one 
• 1361569-21-2 6-amino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-7-(2,2,2-trifluoroethyl)-7,9-dihydro-8H-purin-8-one 

Relevant articles and documents

Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure

The first-in-class soluble guanylate cyclase (sGC) stimulator riociguat was recently introduced as a novel treatment option for pulmonary hypertension. Despite its outstanding pharmacological profile, application of riociguat in other cardiovascular indications is limited by its short half-life, necessitating a three times daily dosing regimen. In our efforts to further optimize the compound class, we have uncovered interesting structure-Activity relationships and were able to decrease oxidative metabolism significantly. These studies resulting in the discovery of once daily sGC stimulator vericiguat (compound 24, BAY 1021189), currently in phase 3 trials for chronic heart failure, are now reported.